Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Amgen's Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer

  • Amgen Inc (NASDAQ:AMGN) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).
  • In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7%, and median duration of response (DOR) of 12.3 months. 
  • Five patients achieved complete responses, and 65 patients achieved partial responses. 
  • Related: Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer.
  • The results also showed median progression-free survival (PFS) of 6.3 months and overall survival (OS) of 12.5 months, with 32.5% of patients still alive at two years. 
  • No new safety signals for Lumakras were identified with the long-term follow-up.
  • Read Next: Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why.
  • Price Action: AMGN shares are up 0.95% at $255.44 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.